From: The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease
Patient group vs control group | Patient group | |||||
---|---|---|---|---|---|---|
Controls (N = 26) | Patients (N = 74) | P | aMCI (N = 35) | AD (N = 39) | P | |
Aβ1-40 | 50.7 ± 4.9 | 52.1 ± 4.2 | 0.160 | 51.9 ± 4.8 | 52.3 ± 3.7 | 0.654 |
Aβ1-42 | 16.9 ± 0.7 | 17.3 ± 1.0 | 0.038 | 17.2 ± 1.1 | 17.4 ± 0.9 | 0.455 |
t-Tau | 23.8 ± 3.9 | 26.6 ± 5.1 | 0.014 | 26.0 ± 5.1 | 27.1 ± 5.2 | 0.374 |
p-Tau181 | 3.7 ± 0.7 | 4.1 ± 0.9 | 0.035 | 4.0 ± 0.9 | 4.2 ± 0.9 | 0.340 |
IL-1β | 0.07 ± 0.04 | 0.12 ± 0.11 | 0.039 | 0.12 ± 0.11 | 0.12 ± 0.12 | 0.765 |
IL-1RA | 63 ± 31 | 96 ± 79 | 0.045 | 108 ± 104 | 85 ± 45 | 0.289 |